Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Clinical Trial of an Alphavirus Replicon Vaccine for Cytomegalovirus (CMV) (CMV)

This study has been completed.
Information provided by:
AlphaVax, Inc. Identifier:
First received: February 23, 2007
Last updated: November 7, 2008
Last verified: November 2008

AVX601, a bivalent alphavirus replicon vaccine expressing three CMV proteins (gB, pp65 and IE1) is a candidate vaccine against cytomegalovirus (CMV).

The objectives of this Phase 1 study are to test the safety of the vaccine and the immune response to the vaccine in healthy volunteers who have not previously been infected with CMV. Volunteers will be assigned by randomization to receive either the vaccine or an inactive substance (placebo) by injections in each arm on three occasions over 6 months. The study will last 12 months and will have a total of 12 visits.

Condition Intervention Phase
Cytomegalovirus Infections
Biological: AVX601
Biological: Placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator)
Primary Purpose: Prevention
Official Title: A Single-Site, Phase 1, Double-Blind, Safety and Immunogenicity Trial of an Alphavirus Replicon Vaccine Expressing Cytomegalovirus Genes (AVX601) in Healthy Volunteers

Resource links provided by NLM:

Further study details as provided by AlphaVax, Inc.:

Primary Outcome Measures:
  • evaluate safety of AVX601 based on teh frequency of Grade 2,3,or 4 systemic reactogenicity events [ Time Frame: 1 year ]

Secondary Outcome Measures:
  • evaluate the immunogenicity of AVX601 in healthy volunteers after 3 doses of vaccine [ Time Frame: 15 months ]

Enrollment: 40
Study Start Date: April 2007
Study Completion Date: July 2008
Primary Completion Date: July 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: T1 Biological: AVX601
3 doses of AVX601 at 1e7 IU given at T=0, 8, 24 weeks via the IM route
Placebo Comparator: C1 Biological: Placebo
3 doses of placebo given at T=0, 8, 24 weeks via the IM route
Active Comparator: T2 Biological: AVX601
3 doses of AVX601 at 1e7 IU given at T=0, 8, 24 weeks via the SC route
Placebo Comparator: C2 Biological: Placebo
3 doses of placebo given at T=0, 8, 24 weeks via the SC route
Active Comparator: T3 Biological: AVX601
3 doses of AVX601 at 1e8 IU given at T=0, 8, 24 weeks via the IM route
Placebo Comparator: C3 Biological: AVX601
3 doses of placebo given at T=0, 8, 24 weeks via the IM route
Active Comparator: T4 Biological: AVX601
3 doses of AVX601 at 1e8 IU given at T=0, 8, 24 weeks via the SC route
Placebo Comparator: C4 Biological: Placebo
3 doses of placebo given at T=0, 8, 24 weeks via the SC route

Detailed Description:
This is a randomized, double-blind, placebo-controlled Phase 1 study of the safety and immunogenicity of AVX601 vaccine at two dosage levels and two routes of administration in healthy volunteers conducted at a single research center. A total of 40 participants will be enrolled into two groups of 20 participants each. Within each group, participants will be randomized to receive the active vaccine by IM injection (N = 8) or SC injection (N = 8) or to receive a placebo by IM injection (N = 2) or SC injection (N = 2). Each participant will receive a total of six injections of vaccine or placebo, two at each visit at Weeks 0, 8 and 24, administered by a study nurse in an outpatient setting, and will be followed for 12 months after the first immunization. Safety data will include local and systemic reactogenicity after each dose of vaccine, collected in a systematic format using a subject memory aid and a standard grading scale, specific safety laboratory parameters and general AEs. Immunogenicity data will be obtained by collecting blood at defined time points before and after immunization and separating serum (for measurement of antibodies to CMV by ELISA and neutralization assays and to the vaccine vector by a VRP neutralization assay) and peripheral blood mononuclear cells (PMBC) (for measurement of cellular immune responses to CMV peptides).

Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Between 18 and 45 years of age, inclusive
  2. Good general health without significant physical examination findings or clinically significant abnormal laboratory results
  3. Available to participate for the entire study period of approximately 12 months
  4. For women of childbearing potential, a negative urine pregnancy test at screening and before each immunization, and agreement to consistently use contraception from 28 days prior to enrollment until the last protocol visit, for sexual activity that could lead to pregnancy
  5. Acceptable laboratory parameters:

    • negative CMV serology
    • hemoglobin ≥ 11.2 g/dL for women, ≥ 12.8 g/dL for men
    • white blood cell count 3,300 - 12,000 cells/mm3
    • platelet count 125,000 - 550,000/mm3
    • alanine aminotransferase (ALT) within normal range for study laboratory
    • serum creatinine within normal range for study laboratory
    • normal urine dipstick (negative glucose, negative hemoglobin, and negative or trace protein)
    • negative hepatitis B virus (HBV) and hepatitis C virus (HCV) blood tests
    • negative HIV blood test
  6. Willingness to have blood stored for up to 10 years for use in additional assays to evaluate immune responses to CMV or the alphavirus vector if such assays become available
  7. Willingness to participate in the study as evidenced by signed informed consent obtained before screening

Exclusion Criteria:

  1. Venous access deemed inadequate for the phlebotomy demands of the study
  2. Women who are breast feeding
  3. In female subjects, a positive urine pregnancy test at screening or on the day of any vaccine injection
  4. Receipt of any vaccine within 30 days prior to enrollment
  5. Use of any investigational agent within 30 days prior to enrollment
  6. Receipt of immunoglobulin or blood products within 60 days prior to enrollment
  7. Use of cytotoxic medications within 6 months prior to enrollment
  8. Use of systemic corticosteroids within 6 months prior to enrollment (except that participants who have completed a course of prednisone, at up to 20 mg per day for up to 7 days, at least 1 month prior to enrollment are eligible for enrollment)
  9. History of serious adverse reactions to any vaccine, including anaphylaxis and related symptoms such as hives, respiratory difficulty, angioedema or abdominal pain
  10. History of immunodeficiency or autoimmune disease
  11. History of diabetes mellitus
  12. History of splenectomy
  13. History of malignancy within the last 3 years (except that participants with a diagnosis of basal cell carcinoma of the skin are eligible for enrollment)
  14. Psychiatric condition that may interfere with the ability to comply with the protocol requirements. Specifically excluded are persons with history of psychosis within the past 3 years or history of suicidal attempt or gesture within the past 3 years.
  15. History of medical, occupational or family problems as a result of alcohol or illicit drug use during the past 12 months
  16. Any condition which leads the investigator to believe that the participant cannot comply with the protocol requirements or that may place the participant at an unacceptable risk for participation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00439803

United States, Ohio
Cincinnati Center for Clinical Research
Cincinnati, Ohio, United States, 45229
Sponsors and Collaborators
AlphaVax, Inc.
Principal Investigator: Robert A Olmsted, Ph.D. AlphaVax, Inc.
  More Information

Additional Information:
Responsible Party: Robert A. Olmsted, Ph.D., AlphaVax, Inc. Identifier: NCT00439803     History of Changes
Other Study ID Numbers: AVX601-001
Study First Received: February 23, 2007
Last Updated: November 7, 2008

Keywords provided by AlphaVax, Inc.:

Additional relevant MeSH terms:
Cytomegalovirus Infections
Herpesviridae Infections
DNA Virus Infections
Virus Diseases processed this record on May 23, 2017